L-asparaginase: toxicity to normal and leukemic human lymphocytes

Area of Science:

• Biochemistry
• Oncology
• Immunology

Background:

• Chronic lymphocytic leukemia (CLL) is a hematologic malignancy characterized by the accumulation of abnormal lymphocytes.
• L-asparaginase is an enzyme used in chemotherapy that depletes asparagine, an amino acid crucial for cancer cell survival.

Purpose of the Study:

• To evaluate the in vitro cytotoxic effects of L-asparaginase derived from Escherichia coli on lymphocytes from CLL patients and healthy individuals.
• To compare the differential toxicity of L-asparaginase against leukemic versus normal lymphocytes.

Main Methods:

• Quantitative in vitro assays were performed using purified L-asparaginase from Escherichia coli.
• Lymphocytes were isolated from 15 patients diagnosed with chronic lymphocytic leukemia and 25 healthy individuals with normal hemograms.
• Cells were incubated with L-asparaginase (10 units/mL) for varying durations (2 and 7 days) to assess toxicity.

Main Results:

• L-asparaginase exhibited significantly greater toxicity towards lymphocytes from 12 out of 15 CLL patients compared to lymphocytes from healthy individuals.
• After 7 days of incubation, L-asparaginase treatment resulted in an average cell kill of 77% for leukemic lymphocytes and 34% for normal lymphocytes.
• Appreciable toxicity to leukemic lymphocytes was observed as early as 2 days of incubation.

Conclusions:

• Purified L-asparaginase from Escherichia coli demonstrates selective toxicity against chronic lymphocytic leukemia lymphocytes in vitro.
• The findings support the potential of L-asparaginase as a therapeutic agent for CLL, warranting further investigation.
• Differential sensitivity of leukemic lymphocytes to L-asparaginase suggests a mechanism for its clinical efficacy.